Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194

1.

Epidermal growth factor induces bladder cancer cell proliferation through activation of the androgen receptor.

Izumi K, Zheng Y, Li Y, Zaengle J, Miyamoto H.

Int J Oncol. 2012 Nov;41(5):1587-92. doi: 10.3892/ijo.2012.1593. Epub 2012 Aug 21.

2.

Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells.

Zheng Y, Izumi K, Yao JL, Miyamoto H.

Endocr Relat Cancer. 2011 Jul 4;18(4):451-64. doi: 10.1530/ERC-11-0010. Print 2011 Aug.

3.

Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action.

Migliaccio A, Di Domenico M, Castoria G, Nanayakkara M, Lombardi M, de Falco A, Bilancio A, Varricchio L, Ciociola A, Auricchio F.

Cancer Res. 2005 Nov 15;65(22):10585-93.

5.

A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.

Recchia AG, Musti AM, Lanzino M, Panno ML, Turano E, Zumpano R, Belfiore A, Andò S, Maggiolini M.

Int J Biochem Cell Biol. 2009 Mar;41(3):603-14. doi: 10.1016/j.biocel.2008.07.004. Epub 2008 Jul 23.

PMID:
18692155
6.

Epidermal growth factor enhances androgen receptor‑mediated bladder cancer progression and invasion via potentiation of AR transactivation.

Hsieh TF, Chen CC, Ma WL, Chuang WM, Hung XF, Tsai YR, Lin MH, Zhang Q, Zhang C, Chang C, Shyr CR.

Oncol Rep. 2013 Dec;30(6):2917-22. doi: 10.3892/or.2013.2792. Epub 2013 Oct 10.

PMID:
24126741
7.
8.

Crosstalk between EGFR and extranuclear steroid receptors.

Migliaccio A, Castoria G, Di Domenico M, Ciociola A, Lombardi M, De Falco A, Nanayakkara M, Bottero D, De Stasio R, Varricchio L, Auricchio F.

Ann N Y Acad Sci. 2006 Nov;1089:194-200.

PMID:
17261767
9.

Crosstalk between androgen receptor and epidermal growth factor receptor-signalling pathways: a molecular switch for epithelial cell differentiation.

Léotoing L, Manin M, Monté D, Baron S, Communal Y, Lours C, Veyssière G, Morel L, Beaudoin C.

J Mol Endocrinol. 2007 Aug;39(2):151-62.

PMID:
17693613
10.

Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.

Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.

Cancer Res. 2004 Oct 1;64(19):7156-68.

11.

Androgen activates β-catenin signaling in bladder cancer cells.

Li Y, Zheng Y, Izumi K, Ishiguro H, Ye B, Li F, Miyamoto H.

Endocr Relat Cancer. 2013 May 20;20(3):293-304. doi: 10.1530/ERC-12-0328. Print 2013 Jun.

12.
13.

Regulation of androgen receptor by androgen and epidermal growth factor in a human prostatic cancer cell line, LNCaP.

Mizokami A, Saiga H, Matsui T, Mita T, Sugita A.

Endocrinol Jpn. 1992 Jun;39(3):235-43.

14.

Epidermal growth factor directs sex-specific steroid signaling through Src activation.

Hitosugi T, Sasaki K, Sato M, Suzuki Y, Umezawa Y.

J Biol Chem. 2007 Apr 6;282(14):10697-706. Epub 2007 Feb 5.

15.

Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer.

Gregory CW, Fei X, Ponguta LA, He B, Bill HM, French FS, Wilson EM.

J Biol Chem. 2004 Feb 20;279(8):7119-30. Epub 2003 Dec 8.

16.

The androgen receptor associates with the epidermal growth factor receptor in androgen-sensitive prostate cancer cells.

Bonaccorsi L, Muratori M, Carloni V, Marchiani S, Formigli L, Forti G, Baldi E.

Steroids. 2004 Aug;69(8-9):549-52.

PMID:
15288768
17.

Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.

Gong J, Zhu J, Goodman OB Jr, Pestell RG, Schlegel PN, Nanus DM, Shen R.

Oncogene. 2006 Mar 30;25(14):2011-21.

PMID:
16434977
18.

Potential action of IGF-1 and EGF on androgen receptor nuclear transfer and transactivation in normal and cancer human prostate cell lines.

Orio F Jr, Térouanne B, Georget V, Lumbroso S, Avances C, Siatka C, Sultan C.

Mol Cell Endocrinol. 2002 Dec 30;198(1-2):105-14.

PMID:
12573820
19.

Compound A Inhibits Bladder Cancer Growth Predominantly via Glucocorticoid Receptor Transrepression.

Zheng Y, Ishiguro H, Ide H, Inoue S, Kashiwagi E, Kawahara T, Jalalizadeh M, Reis LO, Miyamoto H.

Mol Endocrinol. 2015 Oct;29(10):1486-97. doi: 10.1210/me.2015-1128. Epub 2015 Aug 31.

PMID:
26322830
20.

Nur77 inhibits androgen-induced bladder cancer growth.

Wu J, Liu J, Jia R, Song H.

Cancer Invest. 2013 Dec;31(10):654-60. doi: 10.3109/07357907.2013.853077.

PMID:
24299210

Supplemental Content

Support Center